Informações de Abbott Laboratories

Mais detalhes de Abbott Laboratories Empresa

Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.



Código da empresaABT

Nome da EmpresaAbbott Laboratories

Data de listagemMar 01, 1937

CEOMr. Robert B. Ford

Número de funcionários114000

Tipo de títulosOrdinary Share

Fim do ano fiscalMar 01

Endereço100 Abbott Park Road

CidadeABBOTT PARK

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal60064-3500

Telefone12246676100

Sitehttps://www.abbott.com

Código da empresaABT

Data de listagemMar 01, 1937

CEOMr. Robert B. Ford

Executivos da empresa Abbott Laboratories



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Daniel J. Starks

Independent Director

6.73M

+0.02%

Mr. Hubert L. Allen

Executive Vice President, General Counsel, Secretary

191.90K

+3.84%

Mr. Daniel Gesua Sive Salvadori

Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products

133.77K

+6.42%

Ms. Mary K. Moreland

Executive Vice President - Human Resources

95.58K

-0.82%

Ms. Lisa D. Earnhardt

Executive Vice President, Group President - Medical Devices

71.93K

--

Mr. Louis H. (Lou) Morrone

Executive Vice President - Core Diagnostics

66.61K

-0.40%

Mr. Philip P. Boudreau

Chief Financial Officer, Executive Vice President - Finance

50.97K

-0.75%

Dr. Robert J. Alpern, M.D.

Independent Director

40.80K

+4.17%

Ms. Nancy Mckinstry

Lead Independent Director

38.72K

+4.41%

Ms. Sally E. Blount, Ph.D.

Independent Director

34.06K

-2.76%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Daniel J. Starks

Independent Director

6.73M

+0.02%

Mr. Hubert L. Allen

Executive Vice President, General Counsel, Secretary

191.90K

+3.84%

Mr. Daniel Gesua Sive Salvadori

Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products

133.77K

+6.42%

Ms. Mary K. Moreland

Executive Vice President - Human Resources

95.58K

-0.82%

Ms. Lisa D. Earnhardt

Executive Vice President, Group President - Medical Devices

71.93K

--

Mr. Louis H. (Lou) Morrone

Executive Vice President - Core Diagnostics

66.61K

-0.40%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Diabetes Care

1.98B

17.78%

Core Laboratory

1.36B

12.19%

Adult Nutritionals

1.16B

10.39%

Key Emerging Markets

1.06B

9.50%

Pediatric Nutritionals

1.05B

9.46%

Outro

4.53B

40.67%

Por RegiãoUSD

Nome

Receita

Proporção

All other Countries

6.87B

61.62%

United States

4.28B

38.38%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Diabetes Care

1.98B

17.78%

Core Laboratory

1.36B

12.19%

Adult Nutritionals

1.16B

10.39%

Key Emerging Markets

1.06B

9.50%

Pediatric Nutritionals

1.05B

9.46%

Outro

4.53B

40.67%

Distribuição de ações

Atualizado em: sex, 15 de ago

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

9.89%

BlackRock Institutional Trust Company, N.A.

5.09%

State Street Investment Management (US)

4.51%

Capital International Investors

3.46%

Capital Research Global Investors

2.40%

Outro

74.65%

Investidores

Proporção

The Vanguard Group, Inc.

9.89%

BlackRock Institutional Trust Company, N.A.

5.09%

State Street Investment Management (US)

4.51%

Capital International Investors

3.46%

Capital Research Global Investors

2.40%

Outro

74.65%

Tipos de investidores

Investidores

Proporção

Investment Advisor

46.33%

Investment Advisor/Hedge Fund

22.98%

Research Firm

3.62%

Bank and Trust

2.25%

Pension Fund

2.21%

Sovereign Wealth Fund

1.37%

Insurance Company

1.06%

Individual Investor

0.48%

Hedge Fund

0.44%

Outro

19.25%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

4555

1.40B

80.58%

-14.37M

2025Q2

4616

1.41B

81.28%

+6.94M

2025Q1

4644

1.42B

81.42%

+12.91M

2024Q4

4535

1.39B

80.22%

+15.89M

2024Q3

4391

1.36B

78.29%

-11.85M

2024Q2

4400

1.36B

78.24%

-7.03M

2024Q1

4402

1.35B

77.67%

-9.71M

2023Q4

4429

1.35B

77.56%

-11.05M

2023Q3

4298

1.34B

77.39%

-25.33M

2023Q2

4297

1.35B

77.60%

-13.55M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

172.03M

9.88%

+2.96M

+1.75%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

88.52M

5.09%

+696.11K

+0.79%

Jun 30, 2025

State Street Investment Management (US)

78.35M

4.5%

+689.52K

+0.89%

Jun 30, 2025

Capital International Investors

60.14M

3.46%

-6.69M

-10.01%

Jun 30, 2025

Capital Research Global Investors

41.77M

2.4%

-8.97M

-17.68%

Jun 30, 2025

Geode Capital Management, L.L.C.

38.29M

2.2%

+1.39M

+3.77%

Jun 30, 2025

JP Morgan Asset Management

26.38M

1.52%

-2.42M

-8.39%

Jun 30, 2025

Wellington Management Company, LLP

25.05M

1.44%

-4.71M

-15.83%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

22.25M

1.28%

+1.27M

+6.03%

Jun 30, 2025

Wells Fargo Advisors

15.18M

0.87%

-240.50K

-1.56%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 2 de out

Nome

Proporção

iShares U.S. Medical Devices ETF

18.52%

Goldman Sachs Future Health Care Equity ETF

6.46%

SMI 3Fourteen Full-Cycle Trend ETF

5.18%

Tema Heart & Health ETF

4.68%

Health Care Select Sector SPDR Fund

4.64%

Proshares Ultra Health Care

4.64%

iShares U.S. Healthcare ETF

4.44%

AdvisorShares Focused Equity ETF

4.42%

Invesco Pharmaceuticals ETF

4.35%

Polen Capital Global Growth ETF

4.27%

Ver Mais

iShares U.S. Medical Devices ETF

Proporção18.52%

Goldman Sachs Future Health Care Equity ETF

Proporção6.46%

SMI 3Fourteen Full-Cycle Trend ETF

Proporção5.18%

Tema Heart & Health ETF

Proporção4.68%

Health Care Select Sector SPDR Fund

Proporção4.64%

Proshares Ultra Health Care

Proporção4.64%

iShares U.S. Healthcare ETF

Proporção4.44%

AdvisorShares Focused Equity ETF

Proporção4.42%

Invesco Pharmaceuticals ETF

Proporção4.35%

Polen Capital Global Growth ETF

Proporção4.27%

Dividendo



Um total de 16.46B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Dec 13, 2024

ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 19, 2024

ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 15, 2024

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 16, 2024

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Dec 15, 2023

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option

Jan 12, 2024

Feb 15, 2024

Jan 11, 2024

Sep 21, 2023

ABT.NB Final Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 09, 2023

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 17, 2023

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Dec 09, 2022

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 15, 2022

ABT.NB Final Cash Dividend of gross USD 0.47 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

Ver Mais

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados